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Abstract The ability to adapt to cycles of feast and famine is
critical for survival. Communication between multiple meta-
bolic organs must be integrated to properly metabolise nutri-
ents. By controlling networks of genes in major metabolic
organs, nuclear hormone receptors (NHRs) play central roles
in regulating metabolism in a tissue-specific manner. NHRs
also establish daily rhythmicity by controlling the expression
of core clock genes both centrally and peripherally. Recent
findings show that many of the metabolic effects of NHRs are
mediated through certain members of the fibroblast growth
factor (FGF) family. This review focuses on the roles of NHRs
in critical metabolic organs, including adipose tissue, liver and
muscle, during the fed and fasted states, as well as their roles
in circadian metabolism and downstream regulation of FGFs.
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Abbreviations
BMAL1 Brain and muscle ARNT-like 1
CLOCK Circadian locomotor output cycles kaput
CRY Cryptochrome
ERRγ Oestrogen-related receptor γ
FGF Fibroblast growth factor
FXR Farnesoid X receptor
LPL Lipoprotein lipase
LXR Liver X receptor
NHR Nuclear hormone receptor
Nur77 Growth factor-inducible immediate early
gene nur/77-like receptor
PGC1α PPARγ co-activator 1α
PPAR Peroxisome proliferator-activated receptor
REV-ERB Reverse c-erbA
ROR Retinoid orphan receptor
SCN Suprachiasmatic nucleus
TZD Thiazolidinedione
WAT White adipose tissue
Introduction
The ability to navigate through unpredictable environmental
changes such as cycles of feast and famine is critical for the
survival of an organism. In order to adapt to fluctuations in
nutrient availability, communication between multiple meta-
bolic organs must be integrated to properly metabolise carbo-
hydrates, proteins and lipids. Dysregulation of these processes
can have an impact on survival during a fast or lead to obesity
and related pathologies, such as type 2 diabetes, in response to
overnutrition. However, the underlying mechanisms that
maintain metabolic balance during extremes of nutrient chal-
lenge remain poorly understood.
Insight into these mechanisms can be gained by studying
the highly conserved nuclear hormone receptor (NHR) super-
family. The 48 human NHRs are genetic switches that control
networks of genes in response to various physiological cues
and orchestrate a diverse range of biological functions, includ-
ing nutrient homeostasis [1–3]. Typical nuclear receptors are
comprised of distinct functional domains, including an
N-terminal transactivation domain, a highly conserved
DNA-binding domain (DBD) and a C-terminal ligand-
binding domain containing a ligand-dependent transactivation
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function [1, 2]. Ligand binding induces a conformational
change in the receptor that allows for differential recruitment
of cofactors and subsequent modulation of NHR activity
[3–6]. A unique feature of many of these receptors is their
ability to be activated by lipophilic ligands derived from
dietary nutrients such as long chain fatty acids and sterols.
By controlling networks of genes in key metabolic organs,
NHRs play critical roles in regulating the metabolism of
nutrients in a tissue-specific manner [7]. NHRs also regulate
the expression of core clock genes both centrally and periph-
erally to coordinate and establish daily rhythmicity. Recent
studies show that certain members of the fibroblast growth
factor (FGF) family are direct targets of NHRs and responsible
for mediating many of their metabolic effects. Their impor-
tance in metabolism, combined with the ability to manipulate
their ligand-dependent activity, make NHRs attractive drug
targets for the treatment of metabolic disease. Here, we dis-
cuss the roles of NHRs, during feast and famine, in adipose
tissue, liver and muscle, as well as their roles in establishing
circadian rhythms and regulating FGFs.
Adipose tissue
White adipose tissue (WAT) is the major energy reserve in
mammals. The primary function of WAT is to synthesise and
store triacylglycerol during periods of energy excess and to
hydrolyse triacylglycerol to generate fatty acids and glycerol
for use by other organs during periods of energy deprivation
[8]. WAT also secretes adipokines such as leptin and
adiponectin that regulate energy intake, metabolism and insu-
lin sensitivity. Excess storage of triacylglycerol inWAT results
in obesity and related disorders, including type 2 diabetes.
Paradoxically, the metabolic abnormalities found in obesity
are also found in lipodystrophies, which are characterised by
the inability to properly store fat in adipose tissue. Therefore,
an appropriate capacity to store triacylglycerol in WAT in
response to changes in nutrient availability is critical for
metabolic homeostasis.
While multiple NHRs have been shown to affect WAT
metabolism, peroxisome proliferator-activated receptor
(PPAR) γ is the most critical for proper WAT function [9,
10]. PPARγ is most highly expressed in adipose tissue and is
best known for its role in regulating adipogenic and lipogenic
pathways. Generation of whole-body and adipose-specific
PPARγ knockout mice revealed that PPARγ is not only
required for adipocyte differentiation but also for mature
adipocyte function [11–16]. PPARγ also plays a critical role
in glucose homeostasis by increasing the expression of
GLUT4 and c-Cbl-associated protein, as well as numerous
secreted factors that affect insulin sensitivity, such as
adiponectin, resistin, leptin and TNFα in WAT [17–20]
(Fig. 1a). In mice, activation of PPARγ specifically in
adipocytes is sufficient to cause whole-body insulin sensitisa-
tion and, conversely, a dominant-negative mutation in a single
allele of PPARG in humans leads to partial lipodystrophy and
insulin resistance, supporting its role in adipogenesis and
insulin sensitivity [21–24]. The thiazolidinediones (TZDs),
which are known agonists of PPARγ, exhibit potent
adipogenic and glucose-lowering effects, and, despite their
unwanted side effects, remain highly effective for the treat-
ment of metabolic disease [25].
Liver
Maintenance of blood glucose level is a primary requirement
for survival. Although multiple organs are involved in glucose
homeostasis, the liver is the major player. During the fed state,
excess glucose is taken up by the liver and stored as glycogen
via glycogenesis or converted into fatty acids (de novo lipo-
genesis) for synthesis/storage as triacylglycerol. During the
fasted state, stored glycogen is broken down by the liver to
generate glucose by a process called glycogenolysis.
Prolonged fasting or starvation induces de novo glucose syn-
thesis in the liver through hepatic gluconeogenesis. During
starvation, when glycogen stores are depleted and there is a
reliance on fatty acids, the liver also uses acetyl-CoA to
produce ketones, by a process termed ketogenesis.
Several NHRs have been implicated in the control of
glucose homeostasis in the liver (Fig. 1b). The first NHR to
be linkedwith hepatic gluconeogenesis was the glucocorticoid
receptor, which is activated by cortisol. During fasting, in-
creased secretion of cortisol from the adrenal gland increases
the activity of the glucocorticoid receptor in the liver, leading
to transcriptional activation of hepatic gluconeogenic genes
such as glucose-6-phosphatase (G6PC) and phosphoenolpyr-
uvate carboxykinase (PEPCK, also known as PCK1). Other
NHRs, such as hepatocyte nuclear factor 4 (HNF4) and
oestrogen-related receptor γ (ERRγ) have also been shown
to promote hepatic gluconeogenesis during fasting [26, 27].
PPARα is also critical in the liver during the adaptive response
to fasting. PPARα null mice do not present any overt pheno-
type under standard animal housing conditions. However,
when fasted, they exhibit severe hypoglycaemia and impaired
ketogenesis [28–30]. Interestingly, the fatty acid synthase-
dependent phospholipid 1-palmitoyl-2-oleoyl-sn-glycerol-3-
phosphocholine (16:0/18:1-GPC) has been shown to be an
endogenous ligand for PPARα [31]. During the fed state, liver
X receptor (LXR) α and LXRβ, which are activated by
oxysterols, have been shown to suppress gluconeogenic en-
zymes and upregulate the expression of glucokinase to pro-
mote hepatic glucose utilisation [32], while the bile acid
responsive farnesoid X receptor (FXR) suppresses
gluconeogenic genes and increases glycogen synthesis [33].
Diabetologia (2014) 57:860–867 861
In addition to promoting glucose uptake and storage, the
liver plays an important role in cholesterol, bile acid, fatty acid
and triacylglycerol homeostasis. When cholesterol levels are
high, oxysterols generated through cholesterol degradation
activate LXR, which in the liver leads to the formation of bile
acids, to avoid excess accumulation of cholesterol. High levels
of bile acids are sensed by FXR, which inhibits their synthesis
in order to prevent an accumulation of bile acids in the liver.
During the fed state, LXR activation also leads to increased
triacylglycerol accumulation in the liver by increasing the
transcription of genes involved in hepatic de novo lipogenesis
[34]. While PPARα has also been shown to increase the
expression of some genes involved in lipogenesis, it also
promotes the uptake and oxidation of fatty acids in mitochon-
dria, peroxisomes and microsomes [35]. PPARα activation
leads to lower serum triacylglycerol levels through induction
of lipoprotein lipase (LPL) activity via inhibition of apoCIII
(LPL inhibitor) expression [35]. In addition to the hypolipid-
aemic fibrate drugs that target PPARα, it is possible that
targeting of other NHRs in the liver may lead to promising
therapeutics for the metabolic syndrome.
Muscle
Skeletal muscle is composed of multiple myofibres that differ
in their metabolic properties, including oxidative slow-twitch
(type I), mixed oxidative-glycolytic fast-twitch (type IIa) and
glycolytic fast-twitch (type IIb) myofibres [36, 37]. Type I
fibres preferentially oxidise fatty acids, while type II fibres
preferentially metabolise glucose. Adaptation to fasting in
skeletal muscle is aimed at sparing glucose by switching to
fatty acid oxidation. Suppression of glucose utilisation is
accomplished via activation of pyruvate dehydrogenase
kinase 4 (PDK4), which phosphorylates and thus inactivates
the pyruvate dehydrogenase complex to prevent pyruvate
oxidation and conserve lactate and alanine for gluconeogene-
sis [38]. During the fed state, when insulin levels are high,
skeletal muscle handles the majority of glucose disposal in the
body.
NHRs play a critical role in controlling glucose and fatty
acid metabolism in skeletal muscle (Fig. 1c). Growth factor-
inducible immediate early gene nur/77-like receptor (Nur77),
a NHR preferentially expressed in glycolytic vs oxidative
muscle, promotes the expression of genes involved in glucose
metabolism in skeletal muscle [39]. On the other hand,
PPARα, which activates PDK4, promotes lipid utilisation
and inhibits glucose uptake in skeletal muscle [38, 40]. Mice
overexpressing PPARα in skeletal muscle exhibit glucose
intolerance but are protected from high fat diet (HFD)-induced
obesity, while PPARα null mice exhibit enhanced glucose
tolerance, despite increased triacylglycerol accumulation in
muscle and HFD-induced obesity [40]. PPARδ also promotes
fatty acid utilisation in muscle but, in contrast to PPARα,
activation of PPARδ leads to enhanced glucose uptake and
improved skeletal muscle insulin sensitivity, as evidenced by
studies in mice with genetic ablation and ectopic expression of
PPARδ [28, 41–44]. PPARδ has also been shown to activate a
genetic programme that induces a type I endurance muscle































Fig. 1 (a) Adipose tissue during feast and famine. During the fed state,
white adipose tissue (WAT) synthesises and stores energy in the form of
triacylglycerol (TAG). During the fasted state, WAT hydrolyses TAG to
generate NEFA that can be taken up by other organs and used for energy
production. Peroxisome proliferator-activated receptor (PPAR)γ plays a
major role in controlling the expression of genes involved in adipogenesis
and lipogenesis. PPARγ also controls the expression of secreted factors
(transducers) involved in glucose and energy homeostasis such as leptin,
adiponectin, resistin and TNFα as well as fibroblast growth factor (FGF)1
and FGF21, which act locally in adipose tissue during the fed state to
promote adipose remodelling and differentiation, respectively. (b) Liver
during feast and famine. During the fed state, excess glucose is taken up
by the liver and stored as glycogen via glycogenesis or converted to
NEFA through de novo lipogenesis for synthesis and storage as TAG.
During the fasted state, glycogen is broken down to generate glucose via
glycogenolysis. Prolonged fasting leads to de novo glucose synthesis in
the liver through gluconeogenesis (GNG). During starvation, when gly-
cogen stores are depleted, the liver uses acetyl-CoA to produce ketones
by a process called ketogenesis, where PPARα plays an important role.
The glucocorticoid receptor (GR), oestrogen-related receptor γ (ERRγ)
and hepatocyte nuclear factor 4 (HNF4) promote gluconeogenesis, while
liver X receptor (LXR) and farnesoid X receptor (FXR) suppress gluco-
neogenesis. During the fed state, high cholesterol levels activate LXR to
promote the production of bile acids. High bile acid levels are then sensed
by FXR, which inhibits their synthesis to prevent an accumulation of bile
acids in the liver. (c) Skeletal muscle during feast and famine. Type I
fibres preferentially oxidise fatty acids, while type II fibres preferentially
metabolise glucose. PPARγ and ERRγ promote a type I fibre type in
skeletal muscle and PPARα promotes fatty acid utilisation, while Nur77
promotes glucose utilisation
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endurance running and the ability to oxidise both lipids and
carbohydrates at higher rates [42]. In this regard, ERRγ,
which is expressed at much higher levels in type I vs type II
muscle fibres, has been shown to be critical for maintaining
the highly vascularised and oxidative capacity of type I mus-
cle fibres, even in the absence of exercise [45]. This ability to
manipulate oxidative/glycolytic metabolism in skeletal mus-
cle through NHRs represents a potential therapeutic avenue
for treating metabolic disease [46].
Circadian rhythms
Mammals experience natural sleep/wake and fed/fasted cycles
and most physiological processes are regulated in a circadian
manner. These rhythms are generated by a master clock located
in the suprachiasmatic nucleus (SCN) of the hypothalamus,
which synchronises physiology to day/night cycles. While the
master clock, which is entrained by light onto the retina, can
synchronise clocks in peripheral tissues, feeding/fasting rhythms
also serve as strong entrainment factors for metabolic organs.
At the genomic level, NHR signalling is intertwined with
the core clock machinery, which consists of the transcription
factors circadian locomotor output cycles kaput (CLOCK)
and brain and muscle ARNT-like 1 (BMAL1) and their co-
repressors period (PER) and cryptochrome (CRY). NHRs can
be regulated by the clock and can also regulate the clock
themselves. The NHRs reverse c-erbA (REV-ERB)α and
REV-ERBβ along with three retinoid orphan receptors
(RORα, β, γ) regulate many metabolic pathways in a circa-
dian fashion by binding to target genes with an ROR response
element. These receptors reciprocally regulate the expression
of target genes, with RORs serving as constitutive activators
and REV-ERBs acting as repressors [47] (Fig. 2). The
circadian expression pattern of BMAL1 is generated by the
oscillating expression of both RORα and REV-ERBα in the
SCN [48]. REV-ERBα and REV-ERBβ are also involved in
peripheral circadian regulation of liver metabolism by regu-
lating the CLOCK–BMAL1 transcriptomes [49]. Interesting-
ly, haem has been identified as an endogenous ligand for
REV-ERBα/β linking metabolism and circadian clock [50,
51]. Furthermore, many genes involved in both clock and
metabolic functions harbour BMAL1 and REV-ERBα/β
binding sites, indicating an integrated mechanism of circadian
gene expression by these transcription factors [49, 52].
The glucocorticoid receptor also plays a critical role in
establishing circadian rhythmicity [53]. Circulating levels of
glucocorticoids oscillate throughout the day with peak levels
during the onset of activity. The glucocorticoid receptor is also
critical for resetting the clock in peripheral tissues, such as the
liver, and there are glucocorticoid response elements (GREs)
in core clock genes such as PER1 and PER2. It has also been
shown that CRY directly binds to the glucocorticoid receptor
to regulate its activity. In addition to the glucocorticoid recep-
tor, REV-ERBα/β and RORs, many other NHRs have been
shown to be expressed in a circadian fashion and play a role in
circadianmetabolism [54, 55]. In fact, in keymetabolic organs
such liver, muscle and adipose tissue, over half of the NHRs
detected exhibit circadian expression, suggesting that changes
in the expression of NHRs and their downstream target genes
are likely to explain the cyclical behaviour of glucose and lipid
metabolism [55].
The NHR–FGF connection
Recently, NHRs have been shown to exert control on nutri-
tional homeostasis by regulating the expression of four differ-
ent members of the FGF family [25, 56]. FGFs are secreted
heparan sulphate-binding proteins that act locally by signal-
ling through FGF receptors and are typically involved in cell
growth, angiogenesis and wound healing [57, 58]. In contrast,
the endocrine FGFs (FGF 19, 21 and 23) have poor affinity for
heparan sulphate and therefore circulate rather than being
immobilised in the extracellular matrix [58]. While the clas-
sical, paracrine FGFs require heparan sulphate for proper
activation of FGF receptors, the endocrine FGFs require the
α or β Klotho co-receptors for signalling [56, 59]. The endo-
crine FGFs have received much attention for their role as
metabolic regulators and are controlled by NHRs (Fig. 1a).
While FGF23, through its interaction with the vitamin
D receptor, has been shown to be critical for controlling
vitamin D metabolism, we will focus on the FXR–FGF19
and PPAR–FGF21 signalling pathways because of their rele-
vance during feast and famine [56] (Fig. 3).
FGF19 is a postprandial hormone, and the gene encoding







Fig. 2 Circadian metabolism. Circadian rhythms are generated by a
master clock located in the SCN of the hypothalamus, which is entrained
by light on the retina and can synchronise the clocks in peripheral tissues.
Feeding/fasting cues also serve as strong entrainment factors for meta-
bolic organs. REV-ERBs and RORs reciprocally regulate the expression
of target genes, including BMAL1. REV-ERBs act as transcriptional
repressors, while RORs act as activators
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importance of FGF19 (FGF15 in rodents) in maintaining bile
homeostasis has been demonstrated in both rodent studies and
human clinical studies. In addition to its importance in bile
acid metabolism, FGF19 has also been shown to lower blood
glucose, hepatic triacylglycerol and cholesterol levels [60, 61]
and induce protein and glycogen synthesis in the liver inde-
pendently of insulin [62]. However, unlike insulin, FGF19
does not activate the phosphoinositide 3-kinase (PI3K)–Akt
signalling pathway but, rather, signals through the Ras–extra-
cellular signal-related kinase (ERK) pathway to promote pro-
tein and glycogen synthesis [62, 63]. FGF19 also reduces
hepatic gluconeogenesis by repressing the expression of the
transcription cofactor PPARγ co-activator 1α (PGC1α), and
the PGC1α target genes, G6PC and PEPCK, also through a
mechanism distinct from that of insulin [64]. Unlike insulin,
FGF19 does not increase lipogenesis and actually, as men-
tioned above, reduces hepatic triacylglycerol and cholesterol
levels [60, 61]. While there are concerns regarding potential
mitogenic effects [65, 66], its overlapping but unique func-
tions with insulin make FGF19 an attractive target for the
treatment of both type 1 and 2 diabetes.
In addition to FGF19, FGF21 has emerged as a member of
the endocrine FGFs that is regulated by an NHR to control
metabolism. Initially identified as a factor induced by PPARα
in the liver in response to fasting, FGF21 is now recognised as
a key player in the adaptive starvation response, helping to
shift hepatic metabolism from carbohydrates to fatty acids and
ketone bodies [67, 68]. Interestingly, FGF21 also has an
important function in the fed state, where it is induced by
PPARγ and works in a paracrine manner in adipose tissue to
enhance adipogenesis [68, 69]. FGF21 knockout mice exhibit
impaired PPARγ signalling in adipose tissue, reduced adipos-
ity and are resistant to the insulin-sensitising effects, as well as
the undesirable side effects, of the TZDs, which, as mentioned
previously, are PPARγ agonists [67]. Pharmacological admin-
istration of FGF21 reverses hepatic steatosis and improves
glucose homeostasis in rodents and non-human primates
[70–72]. Recent studies have shown that FGF21 exerts its
effects on glucose homeostasis through adiponectin, an
adipokine known to enhance insulin sensitivity [73, 74]. It
remains to be determined whether other metabolic effects of
FGF21 are also mediated through adiponectin. In addition to
its effects on peripheral metabolism, FGF21 was recently
shown to act centrally to promote adaptations to fasting by
increasing glucocorticoid levels, suppressing physical activity
and altering circadian behaviour [75]. Prevention of female
reproduction is a critical adaptation to starvation, and FGF21
has been shown to exert an inhibitory effect on this process by
acting on the SCN in the hypothalamus [76]. Future studies
further addressing how the central and peripheral actions of
FGF21 are coordinated to control metabolism will be an
exciting new avenue of research [75, 76].
While the endocrine family of FGFs has received the most
attention for its role in metabolism, a new role for the non-
endocrine FGF1 in nutrient homeostasis has emerged. As part
of a screen to identify genes that respond to feast and famine
cues, FGF1 was found to be induced in WAT in response to
HFD and repressed during a fast, pointing to an unexpected
metabolic function in both fed-state and fasted-state re-
sponses. FGF1 was also shown to be induced in visceral
adipose tissue in response to HFD or TZD treatment [77].






















Fig. 3 NHR–FGF interface
during feast and famine. During
the fed state PPARγ, which is
activated by fatty acids, increases
the expression of both FGF1 and
FGF21 to promote adipose
remodelling and adipocyte
differentiation, respectively.
During the fed state, bile acids
activate FXR, which increases the
expression of FGF15/19 to
promote bile acid homeostasis.
During the fasted state, fatty acids
activate PPARα to control energy
homeostasis
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FGF1 knockout mice exhibit no phenotype under standard
laboratory conditions, which led to the long-held assumption
that it was dispensable [58]. However, when placed on an
HFD, FGF1 knockout mice develop marked fibrosis in adi-
pose tissue, structurally restricting adipose tissue expansion
and resulting in a severe diabetic phenotype. Even more
striking, upon withdrawal of the HFD the adipose tissue in
these mice fails to properly contract, leading to severe necrosis
of the adipose tissue [77]. The induction of FGF1 expression
in adipose tissue in the fed state is regulated at the genomic
level by PPARγ, identifying a PPARγ–FGF1 signalling axis
crucial for handling cycles of feast and famine.
Concluding remarks
As global regulators of metabolism, NHRs play critical roles
in key metabolic organs during feast and famine. Their im-
portance in metabolism, combined with their ability to be
modulated by small lipophilic ligands, make NHRs one of
the most highly therapeutically targeted protein families, serv-
ing as targets for drugs including glucocorticoids, thyroid
hormone, tamoxifen, fibrates and TZDs. Although these
NHR-targeted drugs are highly effective, there is the potential
to improve on some of these therapies. For example, while
highly effective for treating type 2 diabetes, TZDs are accom-
panied by unwanted side effects, including fluid retention,
weight gain, bone loss and congestive heart failure. New
strategies are being developed for improving TZD-based ther-
apies, one of which involves targeting downstream effectors
of PPARγ, such as FGF21 or, potentially, FGF1. In this
regard, it will be important to dissect the relative roles of these
two FGFs in adipose tissue, since they are both regulated in
the fed state by PPARγ. Recently, a FGF21 analogue has been
shown to improve dyslipidaemia in obese people, however
only a trend toward glucose lowering was observed [78, 79].
Also, bone loss in these individuals was not examined, which
will be important since FGF21 causes bone loss in rodents
[80]. While drugs are being developed for FGF21, it will be
interesting to see what effect, if any, FGF1 has systemically.
Also, the insulin-like properties of FGF19, combined with its
ability to lower triacylglycerol and cholesterol levels and its
nonlipogenic properties, make it an attractive therapeutic tar-
get of the treatment of both type 1 and 2 diabetes. While there
are concerns about potential mitogenic effects of FGF19 [65,
66], therapies designed to dissociate its mitogenic effects from
its metabolic ones might be possible [81]. Additionally,
targeting NHRs that affect circadian metabolism might be an
interesting therapeutic avenue. In this regard, compounds that
act as agonists for REV-ERBs have been suggested to modu-
late the circadian clock and improve metabolic defects in mice
[82, 83]. As our knowledge of NHR action in nutrient homeo-
stasis continues to advance, these critical integrators of
metabolism remain promising therapeutic targets for the treat-
ment of metabolic disease.
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